Dr. Nicolas Daviaud’s organoid research has been published in Biology Open . The research led by Dr. Daviaud was conducted through a 1 st of its kind, non-immune-based human model of MS, which uses patient stem cells to produce cerebral organoids. These ‘mini human brain’ models show tremendous...
New Study Shows How Primary Progressive MS May Differ from Other Forms of MS Provides possible clues for improving diagnosis and treatment Researchers have developed a model for studying primary progressive MS by taking spinal fluid from people with this form of MS and injecting it into mice. These...
In this ‘Peek behind the paper’, we speak to Violaine Harris from the Tisch Multiple Sclerosis Research Center of New York (USA) about her recent research article published in Regenerative Medicine. Dr Harris gives us a summary of her research and shares her insight into the challenges of u...
We opened Tisch MSRCNY's brand-new, state-of-the-art Experimental Research Center (ERC) on Wednesday ! We are so proud of our team and we thank our supportive donor community and our fantastic Board of Directors that helped make it all happen. The Tisch MSRCNY team is looking forward to...
We are incredibly proud to share that Dr. Daviaud's published organoid research will not only be featured in Biology Open, but one of his images has also been selected for the cover of the Volume 12-March 2023 Issue!
"The AAN Annual Meeting offers top-tier education in an array of learning formats, covering nearly every topic and specialty imaginable, all the valuable CME you need for the year, and the most cutting-edge science across all specialties." The meeting will take place in Boston this year from April...
2023 Patient Education Symposium: Where we were, Where we are & Where we are going. The 23rd Annual Tisch MS Research Center of New York Patient Education Symposium took place at the New York Hilton Midtown on March 19th, 2023. Hundreds of attendees gathered to learn about the groundbreaking...
" A study from the Tisch MS Research Center of New York suggests that microglia could be a potential target for mesenchymal stem cell-derived neural progenitor cell (MSC-NP) therapy." Click here to read the full article.
FDA-Approved Phase II Stem Cell Treatment Trial Shows Significant and Diverse Improvements for Multiple Sclerosis (MS) Patients The study, from the Tisch MS Research Center of New York, is the first to link stem cells with a broad array of improvements in multiple areas Progressive MS patients...